Biomay AG Successfully Completes Interim Analysis of Phase IIb Study with the Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32
Biomay announced today that an interim analysis for futility has been successfully completed for an ongoing phase IIb study (clinicaltrials.gov identifier NCT01538979) with its 3rd generation grass pollen allergy vaccine BM32.
Vienna (I-Newswire) December 16, 2013 - The study has enrolled 180 patients and is designed to show a treatment effect over two consecutive pollen seasons. An independent data management committee (DMC) has been appointed to analyze the data from the first treatment year with respect to the primary endpoint combined symptom and medication score (SMS) as well as the safety aspects of the treatment. The DMC has recommended continuation of the study into the next treatment year.
All patients on active treatment will receive the lower of the two initial doses.
Rainer Henning, CEO of Biomay, commented: We are extremely satisfied with the result of this interim analysis of our most advanced product BM32. Reaching this milestone is an important step in the validation of our peptide carrier fusion protein vaccine platform. We are now looking forward with great confidence to the final read-out of the study in the fourth quarter of 2014".
Biomay will welcome a partner for phase III development, registration and marketing of BM32 as well as for the peptide carrier fusion protein platform.
About BM32 and peptide carrier fusion vaccines:
BM32 is an innovative grass pollen allergy vaccine based on recombinant peptide carrier technology invented in the lab of Prof. Rudolf Valenta at the Medical University of Vienna. This is a revolutionary concept, which offers potential for a paradigm shift in the treatment of allergies. The carrier peptide fusion proteins are constructed from the immunogenic viral coat protein PreS from HBV and peptides from the IgE binding epitopes of the allergens in question; the latter have been engineered to lose their IgE binding capacity. BM32 has been designed to protect patients from the debilitating effects of grass pollen exposure and possibly provide long term cure. The product requires only 3 to 4 annual injections and promises to have very limited side effects. The ongoing phase IIb trial is conducted in 11 leading allergy clinics in 6 European countries and has enrolled 180 patients. The study is coordinated by Prof. Johannes Ring (Klinik am Biederstein, Technical University Munich, Germany).
Based on the same technology platform, additional vaccines targeting different allergies (house dust mite, ragweed, birch and cat dander) are in preclinical development and will be advanced to clinical trials in the near future.
About PR&D Public Relations for Research & Development
PR&D - Public Relations for Research & Development
Viennese agency for science-commun More..ication
We inform 11000 science and business journalists
Our clients have at their disposal individual connections to over 2500 scientific and commercial journalists worldwide. An additional 8600 contacts are made available for them quickly and efficiently through trade-specific news services.
Thus equipped, we offer a singularly effective media work in the field of research and development and attain media attention for our clients in a total of 35 countries in Europe, America and Asia.
PR&D provides for a professional and successful implementation of media strategy starting from individual press releases to the supporting of overall media agendas, both at the national and international levels.Less..
PR&D Public Relations for Research & Development
Till C. Jelitto
Phone : +43 1 505 70 44
Published On:December 16, 2013
Print Release:Print Release
If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.
Lake Norman Dermatologist Recognized by the American Board of Dermatology
The Miracles of Apple Cider Vinegar
Using Hypnotherapy to Quit Smoking!
Crystal Synergy Advances To Bring Crystal Energy To A Topical Ointment
Mark McClure and ARP Wave Join Forces With Dr. Jennifer Young in San Jose